Viewing StudyNCT06102928



Ignite Creation Date: 2024-05-06 @ 7:42 PM
Last Modification Date: 2024-10-26 @ 3:12 PM
Study NCT ID: NCT06102928
Status: RECRUITING
Last Update Posted: 2023-10-26
First Post: 2023-10-22

Brief Title: A Clinical Study of the Combination of Anlotinib and Aumolertinib in the First-line Treatment of Advanced NSCLC With EGFR 21L858R Mutation
Sponsor:
Organization: Kunming Medical University

Study Design

Study Type: INTERVENTIONAL
Expanded Access Type Individual: None
Expanded Access Type Intermediate: None
Expanded Access Type Treatment: None
Patient Registry: None
Target Duration: None
Design Allocation:
Design Intervention Model:
Design Intervention Model Description:
Design Masking Description:
Bio Spec Retention: None
Bio Spec Description: None
Enrollment Count: 30
Enrollment Type: ESTIMATED
Design Primary Purpose:
Design Masking:
Phases:
Name
NA
Observational Models:
Time Perspective List:
Who Masked List: